Comparative Pharmacology
Head-to-head clinical analysis: ENDURON versus FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENDURON versus FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE.
ENDURON vs FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption and increasing water excretion.
Fosinopril is an ACE inhibitor that inhibits the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water.
Oral, 2.5–5 mg once daily. Maximum dose 10 mg/day.
1 tablet (fosinopril 10 mg/hydrochlorothiazide 12.5 mg or fosinopril 20 mg/hydrochlorothiazide 12.5 mg) orally once daily. Maximum dose: fosinopril 80 mg/hydrochlorothiazide 50 mg per day.
None Documented
None Documented
Terminal elimination half-life: 24-48 hours (mean 36 hours); prolonged in renal impairment or heart failure, allowing once-daily dosing.
Fosinoprilat: 11.5 h (terminal); Hydrochlorothiazide: 6-15 h (biphasic, terminal phase 10-15 h).
Primarily renal (approximately 50-70% as unchanged drug); biliary/fecal (15-30%); dose adjustment required in renal impairment (CrCl <30 mL/min).
Fosinopril: 45% renal, 55% biliary/fecal; Hydrochlorothiazide: >95% renal (unchanged).
Category C
Category A/B
Thiazide Diuretic
Thiazide Diuretic